February 10, 2021 05:14 AM EST
FDA+

With Lib­tay­o's sec­ond ap­proval, Re­gen­eron digs deep­er in­to PD-1 der­ma­to-on­col­o­gy niche

Amber Tong

With the sixth check­point in­hibitor to en­ter the US mar­ket, Re­gen­eron ex­ecs have in­sist­ed that they can carve out a re­spectable mar­ket share for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Up­dat­ed: Judge halts NIH cuts na­tion­wide af­ter groups, 22 states sue

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times